Fierce Pharma

After CHMP nod, Moderna CEO applauds EU's 'rigorous scientific review'

While the FDA has flip-flopped on whether to review Moderna’s combination influenza and COVID-19 vaccine, it’s full speed ...

Moderna stock surges as FDA reverses course, agrees to review new flu shot

Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week.
Fierce Pharma

Moderna fronts $950M to settle yearslong COVID patent litigation with Genevant, Arbutus

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud. | Moderna will pay $950 ...

Moderna’s stock rallies as settlement of a patent dispute clears vaccine pipeline

The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.
pharmaphorum

Moderna agrees $950m settlement of mRNA jab litigation

Arbutus and Genevant's complaint claimed that Moderna's mRNA-based Spikevax shot used lipid nanoparticle (LNP) delivery ...
Straight Arrow News (English) on MSN

FDA to review Moderna's mRNA flu vaccine after initial rejection

Moderna announced that the FDA will review its new mRNA flu vaccine, a reversal less than two weeks after the agency refused to do so. The post FDA to review Moderna's mRNA flu vaccine after initial ...